Mead Johnson Nutrition Co. (NYSE:MJN) Receives Consensus Rating of “Hold” from Analysts
Shares of Mead Johnson Nutrition Co. (NYSE:MJN) have been assigned an average recommendation of “Hold” from the thirteen analysts that are covering the firm. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $94.45.
A number of brokerages recently weighed in on MJN. Goldman Sachs Group Inc. dropped their price objective on Mead Johnson Nutrition from $96.00 to $85.00 and set a “neutral” rating on the stock in a research report on Tuesday, September 27th. Credit Agricole SA raised Mead Johnson Nutrition from an “underperform” rating to an “outperform” rating and set a $96.00 price objective on the stock in a research report on Wednesday, August 3rd. Deutsche Bank AG set a $88.00 price target on Mead Johnson Nutrition and gave the company a “hold” rating in a research note on Sunday, July 24th. BMO Capital Markets reiterated an “outperform” rating and issued a $97.00 price target on shares of Mead Johnson Nutrition in a research note on Monday, August 1st. Finally, Susquehanna reiterated a “hold” rating and issued a $95.00 price target on shares of Mead Johnson Nutrition in a research note on Monday, August 29th.
In other Mead Johnson Nutrition news, SVP Graciela Monteagudo sold 45,873 shares of the firm’s stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $87.64, for a total value of $4,020,309.72. Following the sale, the senior vice president now directly owns 13,800 shares of the company’s stock, valued at $1,209,432. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Kimberly A. Casiano sold 710 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $89.75, for a total value of $63,722.50. Following the completion of the sale, the director now directly owns 7,110 shares in the company, valued at $638,122.50. The disclosure for this sale can be found here. Corporate insiders own 0.50% of the company’s stock.
A number of hedge funds have recently modified their holdings of MJN. Northwestern Mutual Wealth Management Co. raised its stake in shares of Mead Johnson Nutrition by 11.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,287 shares of the company’s stock valued at $118,000 after buying an additional 131 shares during the last quarter. Pinkerton Retirement Specialists LLC acquired a new stake in shares of Mead Johnson Nutrition during the second quarter valued at approximately $128,000. Checchi Capital Advisers LLC raised its stake in shares of Mead Johnson Nutrition by 2.5% in the second quarter. Checchi Capital Advisers LLC now owns 1,418 shares of the company’s stock valued at $129,000 after buying an additional 35 shares during the last quarter. Feltz Wealth PLAN Inc. acquired a new stake in shares of Mead Johnson Nutrition during the second quarter valued at approximately $180,000. Finally, Ingalls & Snyder LLC acquired a new stake in shares of Mead Johnson Nutrition during the second quarter valued at approximately $214,000. 96.93% of the stock is currently owned by institutional investors.
Mead Johnson Nutrition (NYSE:MJN) traded up 0.11% during midday trading on Monday, hitting $80.26. The company’s stock had a trading volume of 740,268 shares. The company has a market cap of $14.82 billion, a price-to-earnings ratio of 30.20 and a beta of 1.26. The company’s 50-day moving average is $80.38 and its 200 day moving average is $84.69. Mead Johnson Nutrition has a one year low of $65.53 and a one year high of $94.40.
Mead Johnson Nutrition (NYSE:MJN) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.88 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.10. Mead Johnson Nutrition had a negative return on equity of 194.30% and a net margin of 13.28%. The company had revenue of $941.50 million for the quarter, compared to the consensus estimate of $967.25 million. During the same quarter last year, the company earned $0.76 earnings per share. The firm’s revenue for the quarter was down 8.8% compared to the same quarter last year. On average, analysts predict that Mead Johnson Nutrition will post $3.48 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Monday, October 3rd. Investors of record on Monday, September 19th were issued a dividend of $0.4125 per share. This represents a $1.65 annualized dividend and a yield of 2.06%. The ex-dividend date was Thursday, September 15th. Mead Johnson Nutrition’s dividend payout ratio (DPR) is 62.03%.
Mead Johnson Nutrition Company Profile
Mead Johnson Nutrition Company (Mead Johnson) is a pediatric nutrition company. The Company manufactures, distributes and sells infant formulas, children’s nutrition and other nutritional products. The Company operates through three segments: Asia, North America/Europe and Latin America. Its product portfolio includes routine and specialty infant formulas, children’s milks and milk modifiers, dietary supplements for pregnant and breastfeeding mothers, pediatric vitamins, and products for pediatric metabolic disorders.
Receive News & Ratings for Mead Johnson Nutrition Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mead Johnson Nutrition Co. and related companies with MarketBeat.com's FREE daily email newsletter.